Etzer Darout
Stock Analyst at Barclays
(4.66)
# 252
Out of 5,182 analysts
176
Total ratings
55.77%
Success rate
33.22%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Etzer Darout
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| SRRK Scholar Rock Holding | Maintains: Overweight | $53 → $55 | $48.39 | +13.66% | 11 | May 8, 2026 | |
| CLDX Celldex Therapeutics | Maintains: Overweight | $45 → $48 | $33.97 | +41.30% | 5 | May 8, 2026 | |
| JAZZ Jazz Pharmaceuticals | Maintains: Overweight | $225 → $234 | $225.79 | +3.64% | 3 | May 6, 2026 | |
| SNDX Syndax Pharmaceuticals | Maintains: Overweight | $35 → $37 | $21.49 | +72.17% | 2 | May 1, 2026 | |
| ORKA Oruka Therapeutics | Maintains: Overweight | $78 → $160 | $64.59 | +147.72% | 4 | Apr 28, 2026 | |
| ANAB AnaptysBio | Maintains: Overweight | $79 → $63 | $69.30 | -9.09% | 6 | Apr 22, 2026 | |
| TRAX First Tracks Biotherapeutics | Initiates: Overweight | $40 | $19.54 | +104.71% | 1 | Apr 22, 2026 | |
| MGNX MacroGenics | Maintains: Overweight | $4 → $6 | $3.00 | +100.00% | 12 | Apr 20, 2026 | |
| EXEL Exelixis | Maintains: Equal-Weight | $44 → $45 | $48.16 | -6.56% | 7 | Apr 20, 2026 | |
| TVRD Tvardi Therapeutics | Downgrades: Underweight | $4 → $3 | $4.18 | -28.23% | 3 | Apr 20, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underweight | $29 → $14 | $14.18 | -1.23% | 4 | Apr 20, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $17 → $21 | $12.76 | +64.58% | 1 | Apr 8, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $142 → $148 | $122.74 | +20.58% | 2 | Mar 24, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $113 → $119 | $99.36 | +19.77% | 7 | Mar 19, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $10 → $16 | $3.98 | +302.01% | 15 | Mar 19, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $143 → $128 | $94.13 | +35.99% | 5 | Mar 11, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $5 → $7 | $2.95 | +137.29% | 7 | Feb 27, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $26 → $27 | $12.86 | +109.95% | 9 | Feb 26, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $26 → $30 | $9.12 | +228.95% | 1 | Feb 25, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $10 → $11 | $3.62 | +203.87% | 3 | Feb 25, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $116 → $117 | $98.56 | +18.71% | 3 | Feb 18, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $119 → $133 | $86.08 | +54.51% | 5 | Jan 28, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $16 → $28 | $15.55 | +80.06% | 2 | Jan 21, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $16 → $18 | $10.11 | +78.04% | 7 | Dec 17, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Equal-Weight | $16 → $18 | $18.08 | -0.44% | 3 | Dec 17, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $11 → $28 | $9.42 | +197.24% | 1 | Nov 24, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $125 | $63.58 | +96.62% | 1 | Oct 13, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $9 → $13 | $5.37 | +142.09% | 4 | Sep 2, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Market Perform | $22 → $3 | $5.37 | -44.13% | 3 | Feb 11, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $35 | $16.52 | +111.86% | 1 | Dec 6, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $63 | $0.93 | +6,701.25% | 1 | Dec 6, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $28 → $27 | $1.98 | +1,263.64% | 7 | Nov 14, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $132 → $134 | $105.28 | +27.28% | 6 | Nov 13, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $46 → $48 | $26.43 | +81.61% | 3 | Nov 8, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Perform | $118 → $120 | $146.03 | -17.83% | 3 | Oct 30, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Perform | $7 → $6 | $2.39 | +151.05% | 7 | May 10, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $80 → $82 | $182.85 | -55.15% | 4 | Apr 26, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $20 → $19 | $4.44 | +327.93% | 2 | Apr 25, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | $170 | $295.05 | -42.38% | 2 | Feb 3, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $27 → $38 | $107.16 | -64.54% | 2 | Sep 9, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $54 → $52 | $4.93 | +954.77% | 1 | Mar 28, 2018 |
Scholar Rock Holding
May 8, 2026
Maintains: Overweight
Price Target: $53 → $55
Current: $48.39
Upside: +13.66%
Celldex Therapeutics
May 8, 2026
Maintains: Overweight
Price Target: $45 → $48
Current: $33.97
Upside: +41.30%
Jazz Pharmaceuticals
May 6, 2026
Maintains: Overweight
Price Target: $225 → $234
Current: $225.79
Upside: +3.64%
Syndax Pharmaceuticals
May 1, 2026
Maintains: Overweight
Price Target: $35 → $37
Current: $21.49
Upside: +72.17%
Oruka Therapeutics
Apr 28, 2026
Maintains: Overweight
Price Target: $78 → $160
Current: $64.59
Upside: +147.72%
AnaptysBio
Apr 22, 2026
Maintains: Overweight
Price Target: $79 → $63
Current: $69.30
Upside: -9.09%
First Tracks Biotherapeutics
Apr 22, 2026
Initiates: Overweight
Price Target: $40
Current: $19.54
Upside: +104.71%
MacroGenics
Apr 20, 2026
Maintains: Overweight
Price Target: $4 → $6
Current: $3.00
Upside: +100.00%
Exelixis
Apr 20, 2026
Maintains: Equal-Weight
Price Target: $44 → $45
Current: $48.16
Upside: -6.56%
Tvardi Therapeutics
Apr 20, 2026
Downgrades: Underweight
Price Target: $4 → $3
Current: $4.18
Upside: -28.23%
Apr 20, 2026
Downgrades: Underweight
Price Target: $29 → $14
Current: $14.18
Upside: -1.23%
Apr 8, 2026
Maintains: Overweight
Price Target: $17 → $21
Current: $12.76
Upside: +64.58%
Mar 24, 2026
Maintains: Overweight
Price Target: $142 → $148
Current: $122.74
Upside: +20.58%
Mar 19, 2026
Maintains: Overweight
Price Target: $113 → $119
Current: $99.36
Upside: +19.77%
Mar 19, 2026
Maintains: Overweight
Price Target: $10 → $16
Current: $3.98
Upside: +302.01%
Mar 11, 2026
Maintains: Outperform
Price Target: $143 → $128
Current: $94.13
Upside: +35.99%
Feb 27, 2026
Maintains: Overweight
Price Target: $5 → $7
Current: $2.95
Upside: +137.29%
Feb 26, 2026
Maintains: Overweight
Price Target: $26 → $27
Current: $12.86
Upside: +109.95%
Feb 25, 2026
Maintains: Overweight
Price Target: $26 → $30
Current: $9.12
Upside: +228.95%
Feb 25, 2026
Maintains: Overweight
Price Target: $10 → $11
Current: $3.62
Upside: +203.87%
Feb 18, 2026
Maintains: Overweight
Price Target: $116 → $117
Current: $98.56
Upside: +18.71%
Jan 28, 2026
Maintains: Overweight
Price Target: $119 → $133
Current: $86.08
Upside: +54.51%
Jan 21, 2026
Maintains: Overweight
Price Target: $16 → $28
Current: $15.55
Upside: +80.06%
Dec 17, 2025
Maintains: Overweight
Price Target: $16 → $18
Current: $10.11
Upside: +78.04%
Dec 17, 2025
Upgrades: Equal-Weight
Price Target: $16 → $18
Current: $18.08
Upside: -0.44%
Nov 24, 2025
Maintains: Overweight
Price Target: $11 → $28
Current: $9.42
Upside: +197.24%
Oct 13, 2025
Initiates: Overweight
Price Target: $125
Current: $63.58
Upside: +96.62%
Sep 2, 2025
Maintains: Buy
Price Target: $9 → $13
Current: $5.37
Upside: +142.09%
Feb 11, 2025
Downgrades: Market Perform
Price Target: $22 → $3
Current: $5.37
Upside: -44.13%
Dec 6, 2024
Initiates: Outperform
Price Target: $35
Current: $16.52
Upside: +111.86%
Dec 6, 2024
Initiates: Outperform
Price Target: $63
Current: $0.93
Upside: +6,701.25%
Nov 14, 2024
Maintains: Outperform
Price Target: $28 → $27
Current: $1.98
Upside: +1,263.64%
Nov 13, 2024
Maintains: Outperform
Price Target: $132 → $134
Current: $105.28
Upside: +27.28%
Nov 8, 2024
Reiterates: Outperform
Price Target: $46 → $48
Current: $26.43
Upside: +81.61%
Oct 30, 2024
Maintains: Market Perform
Price Target: $118 → $120
Current: $146.03
Upside: -17.83%
May 10, 2024
Maintains: Market Perform
Price Target: $7 → $6
Current: $2.39
Upside: +151.05%
Apr 26, 2024
Maintains: Outperform
Price Target: $80 → $82
Current: $182.85
Upside: -55.15%
Apr 25, 2023
Maintains: Outperform
Price Target: $20 → $19
Current: $4.44
Upside: +327.93%
Feb 3, 2022
Upgrades: Buy
Price Target: $170
Current: $295.05
Upside: -42.38%
Sep 9, 2020
Maintains: Buy
Price Target: $27 → $38
Current: $107.16
Upside: -64.54%
Mar 28, 2018
Maintains: Outperform
Price Target: $54 → $52
Current: $4.93
Upside: +954.77%